Enanta Pharmaceuticals Inc revenue
Enanta Pharmaceuticals Inc's revenue was $65.3m in fiscal 2025, down 3.4% on the year before. Since fiscal 2011 ($41.9m) it has grown at a compound 3.2% a year. Over the last twelve months it was $65.3m.
Revenue history
| Fiscal year | 2011Sept 2011 | 2012Sept 2012 | 2013Sept 2013 | 2014Sept 2014 | 2015Sept 2015 | 2016Sept 2016 | 2017Sept 2017 | 2018Sept 2018 | 2019Sept 2019 | 2020Sept 2020 | 2021Sept 2021 | 2022Sept 2022 | 2023Sept 2023 | 2024Sept 2024 | 2025Sept 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42 | 42 | 32 | 48 | 161 | 88 | 103 | 207 | 205 | 122 | 97 | 86 | 79 | 68 | 65 | 65 |
| Growth on the year before | — | −0.4% | −23.1% | +48.9% | +237.0% | −45.1% | +16.5% | +101.0% | −0.7% | −40.3% | −20.7% | −11.2% | −8.1% | −14.6% | −3.4% | — |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Royalty | $65.3M | 100.0% | ▼ 3.4% |
| Licenses | $0 | 0.0% | — |
From Enanta Pharmaceuticals Inc's 10-K filed November 19, 2025, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Enanta Pharmaceuticals Inc | $65.3m | 0.7% | -6.8% |
| Abcellera Biologics Inc. | $66.2m | 101.3% | -23.0% |
| Clinuvel Pharmaceuticals Ltd | $64.3m | 5.2% | — |
| Cytokinetics Inc | $67.7m | -21.1% | 89.5% |
| Recursion Pharmaceuticals, Inc. | $68.2m | 56.2% | 12.9% |
| Wave Life Sciences, Inc. | $70.9m | 202.3% | 20.7% |
Compare with peers
- Abcellera Biologics Inc. revenue
- Clinuvel Pharmaceuticals Ltd revenue
- Cytokinetics Inc revenue
- Recursion Pharmaceuticals, Inc. revenue
- Wave Life Sciences, Inc. revenue
Head to head: ABCL vs ENTACUVL vs ENTACYTK vs ENTA
More: Biotechnology stocks compared, Health Care sector, rankings of US companies